Recent update on the development of HPV16 inhibitors for cervical cancer

Area of Science:

• Oncology
• Virology
• Molecular Biology

Background:

• Persistent human papillomavirus (HPV) infection is a leading cause of cervical cancer (CC), the fourth most common cancer in women globally.
• HPV-16 and HPV-18 are the predominant subtypes responsible for CC.
• The HPV-16 E6 oncoprotein is a critical factor in CC progression.

Purpose of the Study:

• To review the HPV genome and the pathogenesis of cervical cancer.
• To summarize novel small molecules identified as inhibitors of HPV-16.
• To discuss the potential of these inhibitors and AI in preventing and treating HPV-related cancers.

Main Methods:

• Literature review of HPV genome and CC development.
• Summary of experimental and in-silico studies identifying HPV-16 inhibitors.
• Overview of artificial intelligence applications in HPV-related cancer diagnostics.

Main Results:

• Small molecules targeting HPV-16, particularly the E6 oncoprotein, have been identified.
• Both experimental and computational approaches have yielded potential therapeutic agents.
• Artificial intelligence tools show promise for improved screening and diagnosis of HPV-related cancers.

Conclusions:

• Targeting the HPV-16 E6 oncoprotein is a key strategy for developing novel CC therapies.
• A combination of small molecule inhibitors and AI-driven diagnostics may advance HPV-related cancer management.
• Further research into these inhibitors and diagnostic tools is warranted.